Diabetes drug tested to fight fatty liver disease
NCT ID NCT06982378
Summary
This study aims to see if a common type of diabetes drug (GLP-1 RA) can improve the buildup of harmful fats in the liver of people who have fatty liver disease, diabetes, and obesity. Researchers will compare liver and blood samples from 30 people who have been on the drug for a year to understand its effects. The goal is to learn how the drug changes the liver's fat profile and related genes to better control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.